These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 28490557)

  • 1. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
    Larsen EL; Cejvanovic V; Kjær LK; Vilsbøll T; Knop FK; Rungby J; Poulsen HE
    BMJ Open; 2017 May; 7(5):e014728. PubMed ID: 28490557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
    Jürgens M; Schou M; Hasbak P; Kjær A; Wolsk E; Zerahn B; Wiberg M; Brandt NH; Gæde PH; Rossing P; Faber J; Inzucchi S; Gustafsson F; Kistorp CM
    BMJ Open; 2019 Nov; 9(11):e029098. PubMed ID: 31780586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials.
    Larsen EL; Cejvanovic V; Kjaer LK; Pedersen MT; Popik SD; Hansen LK; Andersen JT; Jimenez-Solem E; Broedbaek K; Petersen M; Weimann A; Henriksen T; Lykkesfeldt J; Torp-Pedersen C; Poulsen HE
    Br J Clin Pharmacol; 2017 Aug; 83(8):1643-1653. PubMed ID: 28185274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
    Dejgaard TF; Knop FK; Tarnow L; Frandsen CS; Hansen TS; Almdal T; Holst JJ; Madsbad S; Andersen HU
    BMJ Open; 2015 Apr; 5(4):e007791. PubMed ID: 25838513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial.
    Thirumathyam R; Richter EA; Goetze JP; Fenger M; Van Hall G; Dixen U; Holst JJ; Madsbad S; Vejlstrup N; Madsen PL; Jørgensen NB
    BMJ Open; 2022 Aug; 12(8):e054100. PubMed ID: 35953245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials.
    Larsen EL; Andersen A; Kjær LK; Eickhoff MK; Frimodt-Møller M; Persson F; Rossing P; Lykkesfeldt J; Knop FK; Vilsbøll T; Rungby J; Poulsen HE
    Free Radic Res; 2023 Feb; 57(2):140-151. PubMed ID: 37171199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
    Johansen NJ; Dejgaard TF; Lund A; Vilsbøll T; Andersen HU; Knop FK
    BMJ Open; 2018 Jun; 8(6):e021861. PubMed ID: 29950475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
    Gessner A; Gemeinhardt A; Bosch A; Kannenkeril D; Staerk C; Mayr A; Fromm MF; Schmieder RE; Maas R
    Cardiovasc Diabetol; 2022 Jan; 21(1):4. PubMed ID: 34991562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of smoking on the urinary excretion of 8-oxodG and 8-oxoGuo in patients with type 2 diabetes.
    Sørensen AS; Kjær LK; Petersen KM; Henriksen T; Cejvanovic V; Pedersen O; Hansen T; Christensen CK; Brandslund I; Poulsen HE
    Scand J Clin Lab Invest; 2017 Jul; 77(4):253-258. PubMed ID: 28287274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
    Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
    BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol.
    Muller ME; Pruijm M; Bonny O; Burnier M; Zanchi A
    Adv Ther; 2018 Jun; 35(6):875-885. PubMed ID: 29802538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
    Færch K; Amadid H; Nielsen LB; Ried-Larsen M; Karstoft K; Persson F; Jørgensen ME
    BMJ Open; 2017 Jun; 7(5):e013802. PubMed ID: 28592573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Shimada A; Hanafusa T; Yasui A; Lee G; Taneda Y; Sarashina A; Shiki K; George J; Soleymanlou N; Marquard J
    Diabetes Obes Metab; 2018 Sep; 20(9):2190-2199. PubMed ID: 29766633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised, placebo-controlled trials.
    Brønden A; Larsen EL; Karstoft K; Henriksen T; Vilsbøll T; Poulsen HE; Knop FK
    J Diabetes Complications; 2020 Feb; 34(2):107446. PubMed ID: 31672458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
    Suhrs HE; Nilsson M; Bové KB; Zander M; Prescott E
    PLoS One; 2022; 17(2):e0263481. PubMed ID: 35148357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
    Heise T; Jordan J; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
    Clin Ther; 2016 Oct; 38(10):2265-2276. PubMed ID: 27692976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary markers of nucleic acid oxidation in Danish overweight/obese children and youths.
    Kloppenborg JT; Fonvig CE; Johannesen J; Bjerrum PJ; Poulsen HE; Holm JC
    Free Radic Res; 2016 Jul; 50(7):691-7. PubMed ID: 26982114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.